Skip to main content

Table 1 (abstract P131). See text for description

From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)

Predictors

Odds Ratio (95% CI)

P value

Score assigned

Recurrent arthritis

3.6 (1.77-7.61)

<0.001

4

Protracted febrile myalgia

8.4 (3.41-31.85)

<0.001

8

Erysipelas-like erythema

1.74 (0.86-3.51)

0.02

2

Exertional leg pain

2.1 (1.16-3.62)

0.01

2

Carrying M694V homozygous mutation

4.2 (2.2-8.06)

<0.001

4

  1. The cut-off value (9) was 87% sensitive and 82% specific to foresee the risk of colchicine resistance in the ROC
  2. Validation of the scoring system with an independent group (cr-FMF=107, colchicine responsive= 1935) revealed that the cut-off value was 82% sensitive and 79% specific to identify the risk of colchicine resistance. Seventy-nine (73.8%) cr-FMF patients and 137 (7.1%) colchicine responsive patients had a total score of more than 9
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096